Mark Schallenberger - Xtant Medical Chief Officer

Xtant Medical Management Efficiency

The company has return on total asset (ROA) of (0.1058) % which means that it has lost $0.1058 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0877) %, meaning that it created substantial loss on money invested by shareholders. Xtant Medical's management efficiency ratios could be used to measure how well Xtant Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Xtant Medical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16 M in 2024.

Similar Executives

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. Xtant Medical operates under Medical Devices classification in the United States and is traded on AMEX Exchange. It employs 116 people. Xtant Medical Holdings (XTNT) is traded on NYSE MKT Exchange in USA. It is located in 664 Cruiser Lane, Belgrade, MT, United States, 59714 and employs 207 people. Xtant Medical is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Xtant Medical Holdings Leadership Team

Xtant Stock Performance Indicators

Additional Tools for Xtant Stock Analysis